Domain Therapeutics Raises $42M in Series A Financing

Domain Therapeutics, a Strasbourg, France- and Montreal, Canada-based biopharmaceutical firm specializing in the analysis and improvement of revolutionary medication focusing on G Protein-Coupled Receptors (GPCRs) in immuno-oncology, closed a US $42m (€39m) Series A financing.

The spherical was co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, with participation from adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and current investor Seventure Partners.

The firm intends to make use of the funds to:

i) conduct the medical improvement of its EP4R antagonist, DT-9081,

ii) advance two further GPCR packages, together with an anti-CCR8 antibody, to the Investigational New Drug software stage, and

iii) progress its discovery-stage pipeline of plenty of first-in-class belongings focusing on GPCRs, recognized by means of its proprietary platforms.

Led by Pascal Neuville, CEO, Domain Therapeutics is a biopharmaceutical firm working in France and Canada, devoted to the invention and improvement of latest drug candidates focusing on G Protein-Coupled Receptors (GPCRs), some of the necessary courses of drug targets. The firm focuses on creating high-value drug candidates to sort out GPCR-mediated immunosuppression in immune-oncology.

The Board of Directors of Domain Therapeutics is now composed of :

  • James Huang (Director, Panacea Venture),
  • Laurence Rulleau (Director, CTI Life Sciences),
  • Roberto de Ponti (Director, 3B Future Health Fund),
  • Emmanuel Fiessinger (Director, Seventure Partners),
  • Youssef Bennani (Chairman of the Board of Directors),
  • Sylvie Ryckebusch (Independent Director),
  • Pascal Neuville (Director and CEO),
  • Katherine Cohen (Observer, Panacea enterprise),
  • Frédéric Lemaître Auger (Observer, adMare BioInnovations),
  • Erwin Boos (Observer, Schroders Capital), and
  • Guillaume Blavier (Observer, Omnes).



Leave a Comment